[PRNewswire] EpiVax Announces Publication of Antigen-Specific Tolerance
Induction by Tregitope in Nature Scientific Reports
(PROVIDENCE, Rhode Island, Nov. 6, 2019 PRNewswire=연합뉴스) EpiVax, Inc. ("EpiVax"), a pioneer in immunoinformatics innovation, announces the publication of "Therapeutic administration of Tregitope-Human Albumin Fusion with Insulin Peptides to promote Antigen-Specific Adaptive Tolerance Induction" in Scientific Reports, 06 Nov 2019 [https://www.nature.com/articles/s41598-019-52331-1 ], a Nature publication. This research highlights Tregitopes as a promising therapy for Type 1 Diabetes (T1D). Administration of Tregitopes in combination with clinically relevant delivery systems and preproinsulin (PPI) were found to reduce the incidence of severe diabetes and to reverse mild diabetes during a 49-day therapeutic study in non-obese diabetic mice.
Tregitopes are novel peptides first discovered in 2008 in human immunoglobulin by Dr. Anne De Groot and William Martin at EpiVax. They are capable of downregulating inflammation in a wide range of autoimmune disease models, transplant and allergy, by engaging regulatory T cells. This approach has been adapted by others seeking to harness the value of Tregitope, including Marieme Dembele of Dr. Bruce Mazer's lab, University of McGill, Montreal, Canada. Dembele will be presenting her findings on antigen specific tolerance induction by Tregitopes at the EpiVax Immunogenicity and Tolerance Seminar [https://epivax.com/events/immunogenicity-and-tolerance-seminar-november-15th-2019 ] on November 15th at Hilton Amsterdam, showing similar success in allergy models where Tregitope is delivered to aid in suppression of asthmatic symptoms. EpiVax is encouraged by these findings and looks forward to a continued bright future for the Tregitope program.
About EpiVax:
EpiVax is a 20-year old privately-held biotechnology company located in Providence, RI, with a broad portfolio of projects, including vaccines and immunotherapies for infectious diseases, autoimmunity and cancer. Scientists at EpiVax, led by co-founders Annie De Groot and Bill Martin, lead the field in immunogenicity risk assessment. For more information, please visit www.EpiVax.com.
EpiVax is currently licensing Tregitope under 1-year options + license agreements. For more information on Tregitope and licensing opportunities, please contact us here [https://epivax.com/about-us/contact-us ].
For a free online version of this published research please visit Scientific Reports here [https://www.nature.com/articles/s41598-019-52331-1 ].
Press Contact:
Dr. Anne De Groot, M.D.
annied@epivax.com
P: (401) 272-2123
M: (401) 952-4227
Logo - https://mma.prnewswire.com/media/542055/EpiVax_Logo.jpg
EpiVax is an immunology company founded in 1998. We develop and employ extensive analytical capabilities in the field of computational immunology. We assess protein therapeutics for immunogenic risk and design more effective (and safer) vaccines. www.EpiVax.com .
Source: EpiVax, Inc.
[편집자 주] 본고는 자료 제공사에서 제공한 것으로, 연합뉴스는 내용에 대해 어떠한 편집도 하지 않았음을 밝혀 드립니다.
(끝)
출처 : PRNewswire 보도자료
Induction by Tregitope in Nature Scientific Reports
(PROVIDENCE, Rhode Island, Nov. 6, 2019 PRNewswire=연합뉴스) EpiVax, Inc. ("EpiVax"), a pioneer in immunoinformatics innovation, announces the publication of "Therapeutic administration of Tregitope-Human Albumin Fusion with Insulin Peptides to promote Antigen-Specific Adaptive Tolerance Induction" in Scientific Reports, 06 Nov 2019 [https://www.nature.com/articles/s41598-019-52331-1 ], a Nature publication. This research highlights Tregitopes as a promising therapy for Type 1 Diabetes (T1D). Administration of Tregitopes in combination with clinically relevant delivery systems and preproinsulin (PPI) were found to reduce the incidence of severe diabetes and to reverse mild diabetes during a 49-day therapeutic study in non-obese diabetic mice.
Tregitopes are novel peptides first discovered in 2008 in human immunoglobulin by Dr. Anne De Groot and William Martin at EpiVax. They are capable of downregulating inflammation in a wide range of autoimmune disease models, transplant and allergy, by engaging regulatory T cells. This approach has been adapted by others seeking to harness the value of Tregitope, including Marieme Dembele of Dr. Bruce Mazer's lab, University of McGill, Montreal, Canada. Dembele will be presenting her findings on antigen specific tolerance induction by Tregitopes at the EpiVax Immunogenicity and Tolerance Seminar [https://epivax.com/events/immunogenicity-and-tolerance-seminar-november-15th-2019 ] on November 15th at Hilton Amsterdam, showing similar success in allergy models where Tregitope is delivered to aid in suppression of asthmatic symptoms. EpiVax is encouraged by these findings and looks forward to a continued bright future for the Tregitope program.
About EpiVax:
EpiVax is a 20-year old privately-held biotechnology company located in Providence, RI, with a broad portfolio of projects, including vaccines and immunotherapies for infectious diseases, autoimmunity and cancer. Scientists at EpiVax, led by co-founders Annie De Groot and Bill Martin, lead the field in immunogenicity risk assessment. For more information, please visit www.EpiVax.com.
EpiVax is currently licensing Tregitope under 1-year options + license agreements. For more information on Tregitope and licensing opportunities, please contact us here [https://epivax.com/about-us/contact-us ].
For a free online version of this published research please visit Scientific Reports here [https://www.nature.com/articles/s41598-019-52331-1 ].
Press Contact:
Dr. Anne De Groot, M.D.
annied@epivax.com
P: (401) 272-2123
M: (401) 952-4227
Logo - https://mma.prnewswire.com/media/542055/EpiVax_Logo.jpg
EpiVax is an immunology company founded in 1998. We develop and employ extensive analytical capabilities in the field of computational immunology. We assess protein therapeutics for immunogenic risk and design more effective (and safer) vaccines. www.EpiVax.com .
Source: EpiVax, Inc.
[편집자 주] 본고는 자료 제공사에서 제공한 것으로, 연합뉴스는 내용에 대해 어떠한 편집도 하지 않았음을 밝혀 드립니다.
(끝)
출처 : PRNewswire 보도자료
